中访网数据 益方生物2025年半年度报告显示，公司营收1916.38万元，同比增长28.85%，净亏损收窄至1.19亿元，主要得益于技术授权收入增长及研发费用减少。核心产品KRAS G12C抑制剂格索雷塞于2024年11月获批上市，2025年被纳入《CSCO非小细胞肺癌诊疗指南》I级推荐。此外，公司SERD靶向药D-0502、URAT1抑制剂D-0120及TYK2抑制剂D-2570临床进展顺利，其中D-2570银屑病III期试验已完成与CDE沟通。报告期内，公司研发投入1.15亿元，同比下降44.73%，主要因格索雷塞注册临床试验结束。公司涉及米拉蒂公司专利权纠纷二审已立案，尚未开庭。截至报告期末，公司累计获发明专利授权138项，核心竞争力未发生重大不利变化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.